Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer.
from Top Health News -- ScienceDaily https://ift.tt/6xt9QEw
Health, Fitness,Dite plan, health tips,athletic club,crunch fitness,fitness studio,lose weight,fitness world,mens health,aerobic,personal trainer,lifetime fitness,nutrition,workout,fitness first,weight loss,how to lose weight,exercise,24 hour fitness,
Labels
Technology
New Post
[recent][newsticker]
MKRdezign
Powered by Blogger.
Post a Comment